Physician profile
Mark Peacock
NPI 1275061475
$10,158.56
in general payments reported to CMS, 2019-2025
52 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $603 · 2022: $2,130 · 2023: $2,890 · 2024: $2,346 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,376 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,376.02 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,483.24 | 2021-2025 | |
| Novo Nordisk INC | $1,154.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $840.04 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $709.26 | 2021-2025 | |
| Amgen INC. | $571.22 | 2021-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $507.89 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $355.87 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $331.62 | 2022-2025 | Caplyta |
| Gilead Sciences, INC. | $308.31 | 2022-2025 | Sunlenca |
| Janssen Pharmaceuticals, INC | $267.82 | 2022-2024 | Xarelto, Spravato |
| Nevro Corp. | $263.45 | 2023 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.74 | 2021-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $255.13 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Lundbeck LLC | $253.59 | 2023-2025 | Rexulti, Vyepti |
| Astellas Pharma US INC | $236.24 | 2022-2025 | Veozah, Myrbetriq |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $214.08 | 2021-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $188.26 | 2021-2024 | |
| Viiv Healthcare Company | $183.78 | 2022-2025 | Apretude, Cabenuva |
| Boston Scientific Corporation | $130.30 | 2023-2025 | Watchman Flx, General - Male Sui |
| Amarin Pharma, INC. | $127.04 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $103.78 | 2022-2025 | Camzyos, Eliquis |
| Antares Pharma, INC. | $98.41 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Sanofi-Aventis U.S. LLC | $94.56 | 2021-2025 | |
| Silk Road Medical, INC. | $93.00 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.32 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $86.91 | 2022-2024 | Gardasil 9, Gardasil, M-M-R II |
| Shield Therapeutics INC | $80.32 | 2023-2024 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $73.42 | 2021-2023 | Trintellix |
| Azurity Pharmaceuticals, INC. | $66.05 | 2023-2025 | Edarbyclor, Edarbi, Azmiro |
| Theratechnologies INC. | $63.88 | 2022-2025 | Trogarzo, Egrifta |
| Jazz Pharmaceuticals INC. | $63.78 | 2021 | |
| Exact Sciences Corporation | $60.88 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $52.33 | 2024-2025 | Symbravo, Auvelity |
| Abbott Laboratories | $49.95 | 2024 | Freestyle Insulinx |
| Medtronic, INC. | $49.22 | 2023-2025 | Intellis Adaptivestim |
| Tris Pharma INC | $40.65 | 2023-2024 | Dyanavel Xr |
| Arbor Pharmaceuticals, INC. | $34.30 | 2021-2022 | |
| Dexcom, INC. | $29.91 | 2022-2023 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $29.78 | 2023-2024 | Heplisav-B |
| Vanda Pharmaceuticals INC. | $28.24 | 2025 | Fanapt, Hetlioz |
| Vbi Vaccine (Delaware) INC. | $27.95 | 2022-2023 | Prehevbrio |
| Novartis Pharmaceuticals Corporation | $25.14 | 2022 | |
| Organon LLC | $20.78 | 2025 | Nexplanon |
| Seqirus USA INC | $19.95 | 2021 | |
| Philips North America LLC | $19.59 | 2024 | (Ck7) Extended Holter |
| Phathom Pharmaceuticals, INC. | $19.40 | 2023 | Voquezna |
| Kyowa Kirin, INC. | $18.79 | 2024 | Crysvita |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.52 | 2022 | |
| Halozyme INC | $16.24 | 2023 | |
| Horizon Therapeutics Plc | $15.66 | 2022 | |
| Nabriva Therapeutics, Plc | $13.78 | 2021 | |
| Inogen, INC. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Peacock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.